| Document |
Document Title |
|
WO/2017/172606A1 |
The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (v...
|
|
WO/2017/160156A1 |
The invention relates to synthetic capasaicin analogs as TRPV1 agonists and uses thereof for prophylactic and therapeutic use.
|
|
WO/2017/160922A1 |
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
|
|
WO/2017/159656A1 |
The present invention provides a composition, specifically a cosmetic composition, containing (A) at least one compound or salt thereof selected from the group consisting of compounds represented by formula (1-1) and salts thereof and co...
|
|
WO/2017/152755A1 |
The present invention provides a substituted biphenyl compound and a pharmaceutical composition thereof, the substituted biphenyl compound being a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt...
|
|
WO/2017/153235A1 |
The invention relates to novel substituted N-cyclo-3-aryl-1-naphthamide derivatives, to methods for producing same, to the use thereof, either alone or in combination, for the treatment and/or prevention of diseases, and to their use for...
|
|
WO/2017/156354A1 |
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure : Formula (I)
|
|
WO/2017/153950A1 |
The 4-hydroxyphenyl-2-oxoethyl carboxylic derivatives of the general formula: R1-A- R2, wherein the core A is: Formula (I) and R1 is phenyl substituted with two C1-C4 alkyl, 1,3-benzodioxolyl or bicyclo[3.3.1]nonanyl and R2 is H, hydroxy...
|
|
WO/2017/155288A1 |
The present invention relates to a polyethylene glycol derivative and use thereof.
|
|
WO/2017/148357A1 |
The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate can be prepared by subjecting a compound to a deprotection reaction. The intermediate can be used as a raw material ...
|
|
WO/2017/147646A1 |
The invention relates to a dual emission fluorescent compound comprising a chromophore suitable for exhibiting an emission at a first wavelength from an excited state; wherein the compound further comprises one or more groups suitable fo...
|
|
WO/2017/150904A1 |
The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a carbamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the p...
|
|
WO/2017/145569A1 |
Provided is a method for producing an N-vinyl carboxylic acid amide, the method focusing on unsaturated aldehydes that are contained as impurities generated during a reaction. The method for producing an N-vinyl carboxylic acid amide is ...
|
|
WO/2017/145022A1 |
Described herein are UV-absorbing vinylic monomers conjugated to 2-aminobenzophenone derivatives and their uses in preparing UV-absorbing contact lenses capable of blocking ultra-violet ("UV") radiation and violet radiation with waveleng...
|
|
WO/2017/145024A1 |
Described herein are water-soluble UV-absorbing vinylic monomers and their uses in preparing UV-absorbing contact lenses capable of blocking ultra-violet ("UV") radiation and optionally (but preferably) violet radiation with wavelengths ...
|
|
WO/2017/143438A1 |
The present document describes a pharmaceutical excipient composition comprising a functionalized anionic polysaccharide having carboxyl groups complexed with an amino acid-divalent cation complex, monolithic solid dosage forms for dual ...
|
|
WO/2017/141512A1 |
Provided is a catalyst represented by general formula (1), where R1-R16 in the general formula (1) individually represent a hydrogen atom or a substituent independently of each other.
|
|
WO/2017/141911A1 |
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...
|
|
WO/2017/141193A1 |
The present invention provides processes for the preparation of sacubitril or salts thereof. The present invention further provides intermediates of Formula IV, V and VI and their use for the preparation of sacubitril or salts thereof.
|
|
WO/2017/137895A1 |
The subject-matter of the present invention relates to the synthesis of new dendrimeric molecules based on polyhydroxylated pyrrolidines obtained by means of Click Chemistry reactions. The proposed molecules inhibit the enzymes N-acetylg...
|
|
WO/2017/131097A1 |
Provided is a pharmaceutical composition for the treatment or prevention of a cognitive disease or disorder, the composition comprising a compound represented by formula (1), an enantiomer thereof or diasteriomer thereof, or a pharmaceut...
|
|
WO/2017/131500A1 |
The present invention relates to: a novel compound having an HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof; and a medical use thereof. A composition, of the present invention, containing a dihydroxyphenyl-based ...
|
|
WO/2017/132014A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing suc...
|
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
|
WO/2017/129272A1 |
The disclosure generally provides methods for preparing compositions comprising alkanolamine alkylamides and polyols. This disclosure further relates to methods for preparing compositions comprising alkanolamine alkylamides and polyols t...
|
|
WO/2017/132021A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing suc...
|
|
WO/2017/125031A1 |
Provided are a supramolecular composite comprising an angiotensin II receptor (AT1) blocking compound, a neutral endopeptidase inhibitor (NEPi), and a pharmaceutically acceptable cation. The invention further provides a method for prepar...
|
|
WO/2017/122649A1 |
Provided is a fluorine atom-containing compound represented by formula (1) below (In the formula, Z represents a predetermined divalent group, each Ar independently represents a predetermined aromatic ring-containing group, and each ArF ...
|
|
WO/2017/118762A1 |
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction.
|
|
WO/2017/114596A1 |
The present invention relates to a crystalline form of the compound according to formula (I) having at least one X-ray powder diffraction peak (CuKα radiation) in the range of from 16.5±0.2 to 18.5±0.2 (2Θ) and/or 17.0±0.2 to 19.5±...
|
|
WO/2017/115284A1 |
The present invention relates to novel co-crystal forms of Agomelatine, process of preparation and solid oral pharmaceutical formulations containing them.
|
|
WO/2017/107789A1 |
Disclosed are a compound having a chiral spirobiindane skeleton and a preparation method therefor. The compound having a chiral condensed ring spirobiindane skeleton of the present invention is represented by formula I or I'. The prepara...
|
|
WO/2017/109061A1 |
The present invention relates to provided spirocyclopropylamine compounds, endowed with a potent KDM1A (LSD1) inhibitory activity, wherein X, R, and R1 are as defined in the specification, pharmaceutical compositions containing such comp...
|
|
WO/2017/102659A1 |
The invention relates to a method for synthesising at least one nitrogen compound belonging to the family of the partially N-hydroxyethylated tertiary 1,6-hexanediamines of the following general formula (I) in which the groups R1, R2 and...
|
|
WO/2017/101791A1 |
Disclosed are a compound and a use thereof in preparing a drug, and in particular, provided in the present invention are: the compound as shown in formula (I) or a stereoisomer, a geometric isomer, a tautomer, a racemate, a nitroxide, a ...
|
|
WO/2017/104897A1 |
The present invention relates to a Tris- or neopentyl glycol-based amphipathic compound, a method for producing same, and a method for extracting, emulsifying, stabilizing or crystallizing a membrane protein by means of the amphipathic c...
|
|
WO/2017/097085A1 |
Disclosed is a preparation method for a eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt, comprising: firstly, obtaining a clear solution of an AHU-377 and diovan trisodium salt compound, a solvent of the clear solut...
|
|
WO/2017/097193A1 |
The present invention provides a method for refining a lisinopril hydride crude product by means of solvent crystallization. The method specifically comprises: adding ketones solvents into a crude product which contains lisinopril hydrid...
|
|
WO/2017/097275A1 |
The invention relates to solid forms of the free acid of sacubitril of formula 1, especially a crystalline form, incl. a method of removing chemical impurities from the crude free acid of sacubitril that is characterized in the use of we...
|
|
WO/2017/099531A1 |
The present invention relates to a novel phenolic acid derivative compound having whitening and antioxidative activities and a use thereof and, more specifically, to a compound represented by chemical formula (1) below, an isomer thereof...
|
|
WO/2017/096772A1 |
Disclosed is a method for preparing an anti-heart-failure medicine LCZ696. The preparing method comprises the following steps (formula (I)): in an organic solvent, a sacubitril dicyclohexylamine salt reacts with valsartan under the effec...
|
|
WO/2017/100213A1 |
The present invention relates to stabilization of one or more component of a PCR or RT-PCR reaction mixture at ambient temperatures. In particular, formulations, compositions, articles of manufacture, kits and methods for substantially s...
|
|
WO/2017/093732A1 |
The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) ...
|
|
WO/2017/093209A1 |
The present invention relates to a process for preparing 3-amino tetrahydropyrans and, more particularly, to an improved method for synthesizing a 2,3,5-substituted tetrahydropyran derivative, intermediate being used in the preparation o...
|
|
WO/2017/089300A1 |
wherein R1 is selected from the group consisting of hydrogen, methyl and ethyl; wherein R2 and R3 each independently are selected from the group consisting of hydrogen and (C1-C4)alkyl or wherein R2 and R3 together with the carbon atom t...
|
|
WO/2017/079753A1 |
Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of a...
|
|
WO/2017/078507A2 |
The present invention relates to a method for efficiently synthesizing acetic acid by using a catalyst (rhodium, iridium, cobalt, nickel, palladium, platinum, or ruthenium) which is used in acetic acid preparation and undergoes an oxidat...
|
|
WO/2017/073797A1 |
The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing th...
|
|
WO/2017/075531A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of l...
|
|
WO/2017/071629A1 |
The invention relates to a polyamine derivative medicinal salt and preparation method and use in preparation of a drug for treating pyemia. The novel compound has good antagonistic action on a plurality of pyemia-causing pathogen-related...
|
